{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:38:35Z","timestamp":1791517115145,"version":"4.3.4"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT\u20102 and STEP 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Participants had body mass index (\n                      <jats:styled-content style=\"fixed-case\">BMI<\/jats:styled-content>\n                      ) \u2265\u200927\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , with \u22651 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ) 7%\u201310% on stable therapy. A heterogeneity assessment confirmed that study and patient baseline characteristics were similar. Bucher\n                      <jats:styled-content style=\"fixed-case\">ITCs<\/jats:styled-content>\n                      compared tirzepatide 10 and 15\u2009mg once\u2010weekly (\n                      <jats:styled-content style=\"fixed-case\">QW<\/jats:styled-content>\n                      ) to semaglutide 2.4\u2009mg\n                      <jats:styled-content style=\"fixed-case\">QW<\/jats:styled-content>\n                      via placebo, all adjunct to a reduced\u2010calorie diet and increased physical activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tirzepatide 10 and 15\u2009mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide. Tirzepatide 15\u2009mg was associated with statistically significant greater odds versus semaglutide of \u22655% and\u2009\u226515% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides. Both tirzepatide doses showed non\u2010significant trends of greater improvements in high\u2010density lipoprotein, low\u2010density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this ITC versus semaglutide 2.4\u2009mg, tirzepatide 10 and 15\u2009mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15\u2009mg with statistically significant improvements in multiple cardiometabolic risk factors crucial in managing obesity or overweight among patients with T2D. Both tirzepatide doses also had a generally similar safety profile to semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Plain Language Summary<\/jats:title>\n                    <jats:sec>\n                      <jats:title>What is the context and purpose of this research study?<\/jats:title>\n                      <jats:p>Excess weight and type 2 diabetes (T2D) are strongly connected, where most patients with T2D have obesity or overweight. Weight management is crucial for improving T2D outcomes and preventing its progression. Weight management comprises behavioural interventions, psychological support, dietary changes and physical activity programmes. Medications may also be prescribed or surgical options may also be considered. Two such medications for weight management are tirzepatide (up to 15\u2009mg) and semaglutide (up to 2.4\u2009mg), which are injected subcutaneously once per week to help control appetite by prolonging patients' feeling of fullness. These medications are also used at different doses to treat T2D.<\/jats:p>\n                      <jats:p>Because there were no clinical trials directly comparing tirzepatide and semaglutide, particularly in patients with both T2D and either obesity or overweight, this study aimed to indirectly compare the effectiveness and safety of tirzepatide and semaglutide for weight management in patients with overweight or obesity and T2D.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>What was done?<\/jats:title>\n                      <jats:p>We indirectly compared the efficacy and safety of two doses of tirzepatide (10 and 15\u2009mg per week) versus semaglutide 2.4\u2009mg per week for weight management in adults with both T2D and either obesity or overweight. We used data from two large clinical trials, SURMOUNT\u20102 and STEP 2, which tested tirzepatide and semaglutide, respectively, against a placebo, all adjunct to diet and exercise. An indirect treatment comparison of tirzepatide and semaglutide was then possible via the placebo arm acting as the common comparator. The similarity of study design and patient populations in the two trials was evaluated and found to be sufficiently close to allow meaningful comparisons. Appropriate statistical methodology was used to facilitate comparisons of the two trials.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>What were the main results?<\/jats:title>\n                      <jats:p>Compared to semaglutide 2.4\u2009mg, the higher dose of tirzepatide (15\u2009mg) was associated with a statistically significant improvement in several outcomes such as weight reduction, glycaemic outcomes and triglycerides, while the lower dose of tirzepatide (10\u2009mg) was associated with some statistically significant improvements (e.g., weight reduction and HbA1c) and had otherwise comparable outcomes to semaglutide. However, both doses of tirzepatide were associated with statistically significant greater reductions in glycated haemoglobin A1c (HbA1c) compared to semaglutide, which is a key target of T2D treatment. Both doses of tirzepatide had a generally similar safety profile compared to semaglutide.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>What is the originality and relevance of this study?<\/jats:title>\n                      <jats:p>Currently, there are no clinical trials that compare tirzepatide and semaglutide directly for the management of obesity and overweight in patients with T2D. Previous studies have compared tirzepatide and semaglutide results from different clinical trials for weight management in patients without T2D, not specifically focusing on patients with T2D.<\/jats:p>\n                      <jats:p>This is the first study to indirectly compare tirzepatide and semaglutide for weight management in people with T2D who also have obesity or overweight. The findings of this study suggest that higher doses of tirzepatide may be more effective than semaglutide for weight reduction and improving other health\u2010related outcomes in these patients.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16508","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T01:00:32Z","timestamp":1750381232000},"page":"4709-4719","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Indirect comparative efficacy and safety of tirzepatide 10 and 15\u2009mg versus semaglutide 2.4\u2009mg for the management of obesity and overweight in patients with type 2 diabetes"],"prefix":"10.1111","volume":"27","author":[{"given":"Andreea","family":"Ciudin","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition, Vall d'Hebron University Hospital  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zimner\u2010Rapuch","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bertrand","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[{"name":"Costello Medical  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Clark","sequence":"additional","affiliation":[{"name":"Costello Medical  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludi","family":"Fan","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Sapin","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Francois","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Lariboisi\u00e8re Hospital, AP\u2010HP University Paris\u2010Cit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.818816"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101356"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161521"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2010.04.012"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622313494986"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17165858"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01511-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2019.312"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10\u20102415"},{"key":"e_1_2_10_12_1","unstructured":"NHS England.NHS Diabetes Prevention Programme (NHS DPP). Accessed January 29 2025 https:\/\/www.england.nhs.uk\/diabetes\/diabetes-prevention\/"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03095-3"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.31478\/201701b"},{"key":"e_1_2_10_17_1","unstructured":"European Medicines Agency (EMA).Wegovy (semaglutide) Summary of Product Characteristics. Accessed January 29 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/wegovy\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_18_1","unstructured":"U.S. Food and Drug Administration (FDA).Wegovy (semaglutide) injection for subcutaneous use. Accessed April 2 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf"},{"key":"e_1_2_10_19_1","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA).Wegovy 2.4 mg Solution for Injection in Pre\u2010filled Pen \u2013 PLGB 04668\/0433. Public Assessment Report. Accessed May 30. 2024 https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/beebbeb97c4051a1d965fe7050835904f621122c"},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency (EMA).Ozempic (semaglutide) Summary of Product Characteristics. Accessed January 29 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ozempic\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_21_1","unstructured":"U.S. Food and Drug Administration (FDA).Ozempic (semaglutide) injection for subcutaneous use. Accessed January 29 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf"},{"key":"e_1_2_10_22_1","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA).Ozempic 2 mg Solution for Injection in Pre\u2010Filled Pen \u2013 PLGB 04668\/0435. Public Assessment Report. Accessed January 29 2025.https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/851066223f7ec7aab00effba53bc55a922cb772e"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_10_25_1","unstructured":"European Medicines Agency (EMA).Mounjaro (tirzepatide) Summary of Product Characteristics. Accessed January 29 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/mounjaro\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_26_1","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA).Mounjaro 15 mg Solution for Injection in Pre\u2010filled Pen \u2013 PLGB 14895\/0323. Public Assessment Report. Accessed January 29 2025.https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/74a8638b13b81668c1f35bf5b2bd68bf433c7d05"},{"key":"e_1_2_10_27_1","unstructured":"U.S. Food and Drug Administration.Mounjaro Full Prescribing Information. Accessed January 29 2025.https:\/\/www.accessdata.fda.gov\/spl\/data\/b597917f\u20109673\u20104331\u2010809d\u201079a538bb943c\/b597917f\u20109673\u20104331\u2010809d\u201079a538bb943c.xml"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14940"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15148"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14775"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125\u2010024\u201006144\u20101"},{"key":"e_1_2_10_36_1","unstructured":"European Medicines Agency (EMA).ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Accessed 29 January 2025.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010e9\u2010r1\u2010addendum\u2010estimands\u2010and\u2010sensitivity\u2010analysis\u2010clinical\u2010trials\u2010guideline\u2010statistical\u2010principles\u2010clinical\u2010trials\u2010step\u20105_en.pdf"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0895\u20104356(97)00049\u20108"},{"key":"e_1_2_10_39_1","unstructured":"DiasS SuttonAJ WeltonNJ AdesA.NICE DSU Technical Support Document 3: Heterogeneity: Subgroups Meta\u2010Regression Bias and Bias\u2010Adjustment. Report by the Decision Support Unit.2011."},{"key":"e_1_2_10_40_1","unstructured":"Health Technology Assessment Coordination Group (HTA CG).Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons.2024."},{"key":"e_1_2_10_41_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2023"},{"key":"e_1_2_10_42_1","unstructured":"National Institute for Health and Care Excellence (NICE).Semaglutide for managing overweight and obesity (GID\u2010TA10765).2022."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300\u2010017\u20100314\u2010z"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2020.100237"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0148"},{"key":"e_1_2_10_46_1","unstructured":"National Institute for Health and Care Excellence (NICE).Type 2 diabetes in adults: management. NICE guideline [NG28]2015."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.330"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:45:58Z","timestamp":1761875158000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/dom.16508"],"URL":"https:\/\/doi.org\/10.1111\/dom.16508","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16508\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16508\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"2025-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}